KA

Kineta, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.